Sorrento Therapeutics, Inc. [NASDAQ: SRNE] dipped by -0.71% on the last trading session, reaching $2.80 price per share at the time. Sorrento Therapeutics, Inc. represents 187.15M in outstanding shares, while the company has a total market value of $527.76M with the latest information.
The Sorrento Therapeutics, Inc. traded at the price of $2.80 with 2.16 million shares were bought and sold during the latest trading session. Over the period of the last 3 months, the average trading volume of SRNE shares recorded 7.20M.
Sorrento Therapeutics, Inc. [NASDAQ:SRNE]: Analyst Rating and Earnings
Its stock price has been found in the range of 1.39 to 6.50. This is compared to its latest closing price of $2.82.
Pay attention for this company’s financial results, of which the next release is scheduled to happen on Fri 20 Mar (In 35 Days).
Fundamental Analysis of Sorrento Therapeutics, Inc. [SRNE]
Now let’s turn to look at profitability: with a current Operating Margin for Sorrento Therapeutics, Inc. [SRNE] sitting at -610.94 and its Gross Margin at +52.49.
This company’s Return on Total Capital is -39.68, and its Return on Invested Capital has reached -34.40%. Its Return on Equity is -99.52, and its Return on Assets is -35.26. These metrics suggest that this Sorrento Therapeutics, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Sorrento Therapeutics, Inc. [SRNE] has generated a Total Debt to Total Equity ratio of 111.37. Similarly, its Total Debt to Total Capital is 52.69, while its Total Debt to Total Assets stands at 34.57. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is -2.25, and its Long-Term Debt to Total Capital is 106.52.
What about valuation? This company’s Enterprise Value to EBITDA is -5.87. The Enterprise Value to Sales for this firm is now 27.93, and its Total Debt to Enterprise Value stands at 0.73. Sorrento Therapeutics, Inc. [SRNE] has a Price to Book Ratio of 1.40.
Shifting the focus to workforce efficiency, Sorrento Therapeutics, Inc. [SRNE] earns $55,479 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.12 and its Total Asset Turnover is 0.04. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 2.91 and its Current Ratio is 2.91. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Sorrento Therapeutics, Inc. [SRNE] has 187.15M shares outstanding, amounting to a total market cap of $527.76M. Its stock price has been found in the range of 1.39 to 6.50. At its current price, it has moved down by -56.92% from its 52-week high, and it has moved up 101.44% from its 52-week low.
This stock’s Beta value is currently 2.86, which indicates that it is 8.12% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 29.05. This stock, according to these metrics, is currently Oversold.
Conclusion: Is Sorrento Therapeutics, Inc. [SRNE] a Reliable Buy?
Sorrento Therapeutics, Inc. [SRNE] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.